Alyeska Investment Group L.P. Purchases 100,000 Shares of CureVac (NASDAQ:CVAC)

Alyeska Investment Group L.P. grew its holdings in CureVac (NASDAQ:CVAC - Free Report) by 25.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 500,000 shares of the company's stock after purchasing an additional 100,000 shares during the period. Alyeska Investment Group L.P. owned about 0.22% of CureVac worth $1,705,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of CVAC. Jane Street Group LLC increased its holdings in CureVac by 239.0% in the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock worth $235,000 after buying an additional 55,867 shares in the last quarter. Barclays PLC bought a new stake in shares of CureVac in the third quarter worth approximately $67,000. China Universal Asset Management Co. Ltd. lifted its position in CureVac by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company's stock valued at $162,000 after purchasing an additional 4,425 shares during the period. Signaturefd LLC boosted its holdings in CureVac by 29.2% in the fourth quarter. Signaturefd LLC now owns 36,140 shares of the company's stock worth $123,000 after purchasing an additional 8,170 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in CureVac by 10.3% in the 4th quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock worth $824,000 after purchasing an additional 22,491 shares during the period. Hedge funds and other institutional investors own 17.26% of the company's stock.

CureVac Price Performance

CVAC stock traded up $0.16 during trading on Monday, reaching $3.63. The company's stock had a trading volume of 326,424 shares, compared to its average volume of 798,841. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The company's fifty day moving average is $3.10 and its 200-day moving average is $3.22. The company has a market capitalization of $814.12 million, a P/E ratio of 6.57 and a beta of 2.43. CureVac has a 1 year low of $2.37 and a 1 year high of $5.28.

CureVac (NASDAQ:CVAC - Get Free Report) last released its earnings results on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). CureVac had a return on equity of 21.98% and a net margin of 20.72%. The business had revenue of $15.44 million for the quarter, compared to analysts' expectations of $6.40 million. On average, research analysts expect that CureVac will post 0.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on CVAC. JMP Securities restated a "market outperform" rating and issued a $16.00 price target on shares of CureVac in a research note on Friday, February 14th. UBS Group decreased their price target on shares of CureVac from $13.00 to $12.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.